Hepcludex (bulevirtide) is the first approved therapy with an indication specifically for chronic hepatitis D virus (HDV) infection, a severe form of viral hepatitis seen in patients co-infected with hepatitis B virus (HBV). The drug prevents the virus from entering liver cells, which helps prevent further infection and damage to the liver.
Hepcludex is a new treatment for the treatment of hepatitis D and an important unmet medical need for patients at risk of cirrhosis, liver failure and liver cancer. Its selective antiviral activity provides a promising option for slowing disease progression and improving long-term liver health outcomes.
